Friday, January 30, 2026 11:13:15 AM
Yes, applications for the Transitional Drug Add-on Payment Adjustment (TDAPA) must be submitted electronically through the Medicare Electronic Application Request Information System (MEARIS).
The typical timeframe for a TDAPA application to become effective is approximately 6 months after the quarterly submission deadline, though the exact duration can vary.
TDAPA Application Process and Timeline
Electronic Submission:
All TDAPA applications under the End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) must be submitted via the online MEARIS platform. Paper submissions are not accepted.
Review Period:
The Centers for Medicare & Medicaid Services (CMS) aims for an effective date for the TDAPA to be one quarter (approximately 3 months) after the effective date of the product's Healthcare Common Procedure Coding System (HCPCS) code, which is usually assigned about three months after the application deadline. This generally results in an effective payment date around 6 months after the application is submitted.
Potential Delays:
A longer evaluation period may be necessary if CMS requests further information or needs a more extensive review to determine eligibility. Inaccurate or missing information can add weeks or months to the timeline.
Payment Duration: Once approved, the TDAPA is paid for a period of two years.
Kiwi
Recent UNCY News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 01:11:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 11:29:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 10:32:02 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/10/2026 06:15:05 PM
- Unicycive shares gain as FDA accepts resubmitted OLC NDA • IH Market News • 01/29/2026 03:01:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:14 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/14/2025 10:09:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 02:12:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:39:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/28/2025 11:30:13 AM
- UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit • PR Newswire (US) • 10/14/2025 06:55:00 AM
- Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY • PR Newswire (US) • 10/02/2025 12:04:00 PM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Unicycive Therapeutics, Inc.(UNCY) Shareholders • PR Newswire (US) • 09/29/2025 12:45:00 PM
- Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY • Business Wire • 09/25/2025 07:19:00 PM
